Development of an automated closed system for generation of human lymphokine-activated killer (LAK) cells for use in adoptive immunotherapy
Authors:
- Linda Mesler MuulLMLinda Mesler Muul
- Kathryn Nason-BurchenalKNKathryn Nason-Burchenal
- Charles S. CarterCCCharles S. Carter
- Herbert CullisHCHerbert Cullis
- Dale SlavinDSDale Slavin
- Cornelia HyattCHCornelia Hyatt
- Elaine P. DirectorEDElaine P. Director
- Susan F. LeitmanSLSusan F. Leitman
- Harvey G. KleinHKHarvey G. Klein
- Steven A. RosenbergSRSteven A. Rosenberg
- 1 August 1987
- journal article
- research article
- Published by Elsevier in Journal of Immunological Methods
- Vol. 101 (2) , 171-181
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Large scale production of human lymphokine activated killer cells for use in adoptive immunotherapyJournal of Immunological Methods, 1986
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo.The Journal of Immunology, 1985
- An enzymatic method for the consistent production of monodispersed viable cell suspensions from human solid tumorsJournal of Surgical Oncology, 1985
- Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2Science, 1984
- Biological Activity of Recombinant Human Interleukin-2 Produced in Escherichia coliScience, 1984